Overview
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
Status:
Completed
Completed
Trial end date:
2012-05-01
2012-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Medicines Development for Global Health
World Health OrganizationCollaborator:
World Health OrganizationTreatments:
Ivermectin
Milbemycin
Moxidectin
Criteria
Inclusion Criteria:- Male and female subjects with Onchocerca volvulus infection
Exclusion Criteria:
- Pregnant or breast feeding women; coincidental loiasis